The paper by Yoshihiro Omachi from our company's Formulation Technology Research Headquarters has been published in the academic journal "AAPS PharmSciTech" issued by the American Pharmacists Association.
Gastric retention drug delivery systems (GRDDS) are a formulation technology that retains orally administered formulations in the stomach to gradually release the drug, thereby delaying the transition of the drug to the small intestine and sustaining drug absorption. However, drugs that are difficult to dissolve or unstable in acidic environments have been considered unsuitable for GRDDS. In this study, we designed a GRDDS combined with a self-microemulsifying drug delivery system (SMEDDS) for drugs that have issues with solubility and stability in the stomach.
Inquire About This Product
basic information
The detailed content of the column can be viewed through the related link. For more information, please feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
*You can view the detailed content of the column through the related link. For more information, please feel free to contact us.*
Company information
Our company is a pharmaceutical CMC research and development contract company that spun out from the CMC research division of Takeda Pharmaceutical Company Limited in July 2017. We support excellent pharmaceutical development as experts in CMC research. Our research team consists of experts with extensive experience and achievements in process chemistry, formulation research and development, and analytical testing development related to CMC research. We provide high-level services and solutions tailored to our customers' needs across each process from the early stages of pharmaceutical development to application, while flexibly collaborating. We have established a collaborative system with partner companies, enabling us to offer a one-stop service. Please utilize us as a platform for your pharmaceutical development.